ArticlePloS one2025
Assessing the burden of severe nausea and vomiting of pregnancy or hyperemesis gravidarum and the associated use and experiences of medication treatments: An Australian consumer survey.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Dispensing of Antiemetics During Pregnancy in Aotearoa New Zealand, 2005-2020.The Australian & New Zealand journal of obstetrics & gynaecology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is little data on contemporary patterns of antiemetic use or women's experiences when using such agents in the treatment of severe nausea and vomiting of pregnancy (NVP) or hyperemesis gravidarum (HG).
methodsOnline, national survey of Australian women who were currently or had previously experienced severe NVP or HG, distributed through the HG consumer group, Hyperemesis Australia between July and September 2020.
resultsThere were a total of 289 respondents with a mean age of 33 years, of which 38% were currently pregnant. More than 50% of respondents reported "major impacts" of the condition on areas such as social life, ability to undertake daily chores, ability to eat or drink, effects on work, taking care of pre-existing children and sleep. This resulted in 62% of respondents reporting 'often' or 'always' experiencing feelings of depression or anxiety as a result of their HG symptoms, with 54% reporting considering terminating their pregnancy, and 90% having considered having no more children. The most commonly used anti-emetic was ondansetron (91%), followed by pyridoxine (62%), doxylamine (62%), and metoclopramide (61%). Nearly all (95%) women who reported using ondansetron commenced it within the first trimester, with 55% reporting use as a first-line therapy. Most women reported one or more side effects to anti-emetics such as headache, constipation, sedation or impaired cognition, with 31% stopping metoclopramide because of side effects, compared with 14% for ondansetron and 10% for doxylamine. Ondansetron, doxylamine and corticosteroids had the greatest perceived effectiveness, with more than 50% rating them as "effective" or "very effective". Half (50%) reported use of acid suppressive therapy, with 51% reporting using complementary or alternative therapies in addition to conventional treatments.
conclusionsThe study findings demonstrate large variability in antiemetic use and outcomes, highlighting the need for individualised care and treatment approaches during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.